medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2018-19-96-100medsovet-2754Research ArticleОнкоурологияOncourologyАналоги лютеинизирующего гормона рилизинг-гормона в терапии больных раком предстательной железыLuteinizing hormone releasing hormone analogues in the treatment of patients with prostate cancerАлексеевБ. Я.AlexeevB. Ya.

д.м.н., профессор, заместитель генерального директора по научной работе

НюшкоК. М.NyushkoK. M.

к.м.н., ведущий научный сотрудник отделения онкоурологии

КапринА. Д.KaprinA. D.

д.м.н., профессор, академик РАН, генеральный директор

ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России, МоскваРоссияNational Medical Research Radiological Center, Federal State Budgetary Institution of the Ministry of Health of Russia, MoscowRussian FederationМосковский научно-исследовательский онкологический институт им. П.А. Герцена – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии им. П.А. Герцена» Минздрава России, МоскваРоссияHertsen Moscow Research Institute of Oncology (Moscow) - a branch of Hertsen National Medical Research Radiology Center of the Ministry of Health of Russia, MoscowRussian Federation20181111201801996100Copyright © Алексеев Б.Я., Нюшко К.М., Каприн А.Д., 20182018Алексеев Б.Я., Нюшко К.М., Каприн А.Д.Alexeev B.Y., Nyushko K.M., Kaprin A.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/2754

Рак предстательной железы (РПЖ) является наиболее актуальной онкоурологической патологией по причине неуклонного роста заболеваемости и смертности от данной патологии в Российской Федерации. Частота выявления распространенных форм заболевания остается высокой. Основным методом терапии метастатического РПЖ является комбинированная химио-гормональная терапия. Рефрактерность опухоли к проводимой кастрационной терапии является неотвратимым этапом течения болезни у всех больных, получающих андроген-депривационную терапию. Тем не менее кастрационная терапия, направленная на снижение эндогенного тестостерона у данного контингента больных, должна быть продолжена. Одним из наиболее исследованных препаратов для проведения медикаментозной кастрационной терапии у больных РПЖ является Элигард, эффективность которого доказана многочисленными клиническими исследованиями как в непрерывном, так и интермиттирующем режиме с использованием депо-форм различной продолжительности действия. В статье представлен обзор данных клинических исследований, оценивших эффективность терапии препаратом Элигард в различных режимах и с применением депо-форм разной продолжительности действия, которые продемонстрировали их равную эффективность.

Prostate cancer (PC) is the most pressing oncourological pathology due to a steady increase in morbidity and mortality from this pathology in the Russian Federation. The detection frequency of the common forms of the disease remains high. The combined chemo-hormonal therapy is the main method of treatment of metastatic prostate cancer. The refractoriness of the tumour to the ongoing castration therapy is an inevitable stage of the course of the disease in all patients receiving androgen deprivation therapy. However, castration therapy aimed at reducing endogenous testosterone in this cohort of patients should be continued. Eligard is one of the most studied drugs to conduct the drug castration therapy in patients with prostate cancer, which efficacy has been proven in numerous clinical studies in both continuous and intermittent mode using depot forms of various durations of action. The article presents a review of clinical studies that assessed the efficacy of Eligard therapy in different regimens and with the use of depot forms of various duration, which demonstrated equal effectiveness of such forms.

рак предстательной железыметастазыкастрационная терапияаналоги лютеинезин-гормон-рилизинг гормонаЭлигардProstate cancermetastasescastration therapyluteinzin-hormone-releasing hormone analoguesEligardReferencesКаприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2017 году: заболеваемость и смертность. М., 2018.Kaprin AD, Starinsky VV, Petrova GV. Malignant neoplasms in Russia, 2017: morbidity and mortality, Moscow, 2018.Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2017 г. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018Kaprin AD, Starinsky VV, Petrova GV. The state of cancer care in Russia, 2017. Moscow, Hertsen Moscow Research Institute of Oncology (Moscow) - a branch of Hertsen National Medical Research Radiology Center of the Ministry of Health of Russia, 2018.Матвеев В.Б., Бабаев Э.Р. Факторы прогноза выживаемости больных распространенным раком предстательной железы, получающих гормонотерапию. Онкоурология, 2011, 2: 78-83.Matveev VB, Babaev ER. Predicting factors for survival in patients with advanced prostate cancer receiving hormone therapy. Onkourologia, 2011, 2: 78-83.Матвеев В.Б., Бабаев Э.Р. Влияние гормонотерапии на качество жизни больных распространенным раком предстательной железы. Вестник РНЦРР МЗ России, 2011, 11: 132-134.Matveev VB, Babaev ER. Impact of hormone therapy on quality of life in patients with advanced prostate cancer. Vestnik RNCRR MZ Rossii, 2011, 11: 132-134Oefelein MG, et al. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology, 2000, 56: 1021-4.Oefelein MG, et al. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology, 2000, 56: 1021-4.Klotz L, O’Callaghan C, Ding K, et al. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol, 2015 Apr 1, 33(10): 1151-6. doi: 10.1200/JCO.2014.58.2973.Klotz L, O’Callaghan C, Ding K, et al. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol, 2015 Apr 1, 33(10): 1151-6. doi: 10.1200/JCO.2014.58.2973.Perachino M, Cavalli V, Bravi F. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int, 2009, 105: 648–51.Perachino M, Cavalli V, Bravi F. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance? BJU Int, 2009, 105: 648–51.Bertaglia V, Tucci M, Fiori C et al. Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer. Clin Genitourin Cancer, 2013, 11: 325–30.Bertaglia V, Tucci M, Fiori C et al. Effects of serum testosterone levels after 6 months of androgen deprivation therapy on the outcome of patients with prostate cancer. Clin Genitourin Cancer, 2013, 11: 325–30.Dason S, Allard CB, Tong J, Shayegan B. Defining a new testosterone threshold for medical castration: Results from a prospective cohort series. Can Urol Assoc J, 2013, 7: e263–7.Dason S, Allard CB, Tong J, Shayegan B. Defining a new testosterone threshold for medical castration: Results from a prospective cohort series. Can Urol Assoc J, 2013, 7: e263–7.McLeod D, Zinner N, Tomera K, et al. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology, 2001 Nov, 58(5): 756-61.McLeod D, Zinner N, Tomera K, et al. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology, 2001 Nov, 58(5): 756-61.Morote J, Esquena S, Abascal JM, et al. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer. Urol Int, 2006, 77(2): 135-8.Morote J, Esquena S, Abascal JM, et al. Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer. Urol Int, 2006, 77(2): 135-8.Schulman C. Assessing the attitudes to prostate cancer treatment among European male patients. BJU Int, 2007 Jul, 100(Suppl 1): 6-11.Schulman C. Assessing the attitudes to prostate cancer treatment among European male patients. BJU Int, 2007 Jul, 100(Suppl 1): 6-11.Schulman C, Alcaraz A, Berges R, et al. Expert opinion on 6-monthly luteinizing hormonereleasing hormone agonist treatment with the single-sphere depot system for prostate cancer. BJU Int, 2007 Jul, 100(Suppl 1): 1-5.Schulman C, Alcaraz A, Berges R, et al. Expert opinion on 6-monthly luteinizing hormonereleasing hormone agonist treatment with the single-sphere depot system for prostate cancer. BJU Int, 2007 Jul, 100(Suppl 1): 1-5.Perez-Marrero R, Tyler RC. A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer. Expert Opin Pharmacother, 2004, 5(2): 447-457.Perez-Marrero R, Tyler RC. A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer. Expert Opin Pharmacother, 2004, 5(2): 447-457.Sartor O. Eligard: leuprolide acetate in a novel sustained-release delivery system. Urology, 2003 Feb, 61(2 Suppl 1): 25-31.Sartor O. Eligard: leuprolide acetate in a novel sustained-release delivery system. Urology, 2003 Feb, 61(2 Suppl 1): 25-31.Tunn UW. A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients. BMC Urology, 2011, 11: 15. doi:10.1186/1471-2490-11-15.Tunn UW. A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients. BMC Urology, 2011, 11: 15. doi:10.1186/1471-2490-11-15.Spitz A, Young JM, Larsen L, Mattia-Goldberg C, Donnelly J and Chwalisz K. Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer. Prostate Cancer and Prostatic Diseases, 2012, 15: 93–99. doi:10.1038/ pcan.2011.50; published online 25 October 2011.Spitz A, Young JM, Larsen L, Mattia-Goldberg C, Donnelly J and Chwalisz K. Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer. Prostate Cancer and Prostatic Diseases, 2012, 15: 93–99. doi:10.1038/ pcan.2011.50; published online 25 October 2011.Матвеев В.Б., Бабаев Э.Р. Сравнительный анализ результатов постоянной и интермиттирующей гормонотерапии распространенного рака предстательной железы. Онкоурология, 2011, 1: 51-56.Matveev VB, Babaev ER. Comparative analysis of the results of continuous and intermittent hormone therapy for advanced prostate cancer. Onkourologia, 2011, 1: 51-56.EUA Guidelines on prostate cancer, 2018 edition.EUA Guidelines on prostate cancer, 2018 edition.Crawford ED, Sartor O, Chu F, et al. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol, 2006 Feb, 175(2): 533-6.Crawford ED, Sartor O, Chu F, et al. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol, 2006 Feb, 175(2): 533-6.Calais da Silva FE, Bono AV, Whelan P et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol, 2009 Jun, 55(6): 1269-77. Epub 2009 Feb 21.Calais da Silva FE, Bono AV, Whelan P et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol, 2009 Jun, 55(6): 1269-77. Epub 2009 Feb 21.Hussain M, Tangen CM, Higano C, et al. Southwest Oncology Group Trial 9346 (INT0162). Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol, 2006, 24(24): 3984-90.Hussain M, Tangen CM, Higano C, et al. Southwest Oncology Group Trial 9346 (INT0162). Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol, 2006, 24(24): 3984-90.Hussain M, Tangen CM, Higano CS, et al. Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): results of SWOG 9346 (INT-0162), an international phase III trial. J Clin Oncol, 2012, 30(suppl; abstr4).Hussain M, Tangen CM, Higano CS, et al. Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): results of SWOG 9346 (INT-0162), an international phase III trial. J Clin Oncol, 2012, 30(suppl; abstr4).

The authors declare that there are no conflicts of interest present.